{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T04:07:59Z","timestamp":1790222879858,"version":"4.1.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","atherosclerosis-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1016\/j.atherosclerosis.2016.03.017","type":"journal-article","created":{"date-parts":[[2016,3,25]],"date-time":"2016-03-25T04:15:32Z","timestamp":1458879332000},"page":"215-223","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib in Japanese patients with heterozygous familial hypercholesterolemia"],"prefix":"10.1016","volume":"249","author":[{"given":"Hidenori","family":"Arai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamio","family":"Teramoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Daida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsunori","family":"Ikewaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariko","family":"Nakagomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayoshi","family":"Shirakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taro","family":"Kakikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotaka","family":"Numaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy O.","family":"Johnson-Levonas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanskruti","family":"Vaidya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert O.","family":"Blaustein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.atherosclerosis.2016.03.017_bib1","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1172\/JCI107332","article-title":"Hyperlipidemia in coronary heart disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia","volume":"52","author":"Goldstein","year":"1973","journal-title":"J.\u00a0Clin. Investig."},{"issue":"2","key":"10.1016\/j.atherosclerosis.2016.03.017_bib2","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.jacl.2014.01.002","article-title":"Integrated guidance on the care of familial hypercholesterolemia from the International FH Foundation","volume":"8","author":"Watts","year":"2014","journal-title":"J.\u00a0Clin. Lipidol."},{"issue":"9","key":"10.1016\/j.atherosclerosis.2016.03.017_bib3","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1093\/eurheartj\/ehu058","article-title":"Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype phenotype relationship, and clinical outcome","volume":"36","author":"Sjouke","year":"2015","journal-title":"Eur. Heart J."},{"issue":"3 Suppl","key":"10.1016\/j.atherosclerosis.2016.03.017_bib4","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1016\/j.jacl.2011.03.452","article-title":"National Lipid Association Expert Panel on Familial Hypercholesterolemia. Familial hypercholesterolemias: prevalence, genetics, diagnosis and screening recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia","volume":"5","author":"Hopkins","year":"2011","journal-title":"J.\u00a0Clin. Lipidol."},{"issue":"19","key":"10.1016\/j.atherosclerosis.2016.03.017_bib5","doi-asserted-by":"crossref","first-page":"6919","DOI":"10.1073\/pnas.84.19.6919","article-title":"Familial defective apolipoprotein B-100: low density lipoproteins with abnormal receptor binding","volume":"84","author":"Innerarity","year":"1987","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"4","key":"10.1016\/j.atherosclerosis.2016.03.017_bib6","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1002\/humu.20882","article-title":"Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease","volume":"30","author":"Abifadel","year":"2009","journal-title":"Hum. Mutat."},{"issue":"6","key":"10.1016\/j.atherosclerosis.2016.03.017_bib7","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1111\/j.1365-2796.2004.01405.x","article-title":"The contribution of classical risk factors to cardiovascular disease in familial hypercholesterolaemia: data in 2400 patients","volume":"256","author":"Jansen","year":"2004","journal-title":"J.\u00a0Intern. Med."},{"issue":"10","key":"10.1016\/j.atherosclerosis.2016.03.017_bib8","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/nrcardio.2015.92","article-title":"Management of patients with familial hypercholesterolaemia","volume":"12","author":"Reiner \u017d","year":"2015","journal-title":"Nat. Rev. Cardiol."},{"issue":"3","key":"10.1016\/j.atherosclerosis.2016.03.017_bib9","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.amjcard.2015.04.062","article-title":"Familial hypercholesterolemia and the 2013 American College of Cardiology\/American Heart Association Guidelines: myths, oversimplification, and misinterpretation versus facts","volume":"116","author":"Knowles","year":"2015","journal-title":"Am. J. Cardiol."},{"issue":"6","key":"10.1016\/j.atherosclerosis.2016.03.017_bib10","doi-asserted-by":"crossref","first-page":"517","DOI":"10.5551\/jat.15792","article-title":"Executive summary of the Japan Atherosclerosis Society (JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan -2012 version","volume":"20","author":"Teramoto","year":"2013","journal-title":"J.\u00a0Atheroscler. Thromb."},{"issue":"25 Pt B","key":"10.1016\/j.atherosclerosis.2016.03.017_bib11","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1016\/j.jacc.2013.11.002","article-title":"2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"63","author":"Stone","year":"2014","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"issue":"45","key":"10.1016\/j.atherosclerosis.2016.03.017_bib12","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.1093\/eurheartj\/eht273","article-title":"Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society","volume":"34","author":"Nordestgaard","year":"2013","journal-title":"Eur. Heart J."},{"issue":"3 Suppl","key":"10.1016\/j.atherosclerosis.2016.03.017_bib13","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jacl.2011.04.003","article-title":"Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia","volume":"5","author":"Goldberg","year":"2011","journal-title":"J.\u00a0Clin. Lipidol."},{"issue":"12","key":"10.1016\/j.atherosclerosis.2016.03.017_bib14","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1016\/j.cjca.2014.09.028","article-title":"Canadian Cardiovascular Society position statement on familial hypercholesterolemia","volume":"30","author":"Genest","year":"2014","journal-title":"Can. J. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2016.03.017_bib15","doi-asserted-by":"crossref","first-page":"a2423","DOI":"10.1136\/bmj.a2423","article-title":"Efficacy of statins in familial hypercholesterolaemia: a long term cohort study","volume":"337","author":"Versmissen","year":"2008","journal-title":"BMJ"},{"issue":"21","key":"10.1016\/j.atherosclerosis.2016.03.017_bib16","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1093\/eurheartj\/ehn422","article-title":"Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study","volume":"29","author":"Neil","year":"2008","journal-title":"Eur. Heart J."},{"issue":"2","key":"10.1016\/j.atherosclerosis.2016.03.017_bib17","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.amjcard.2011.03.027","article-title":"Effect of lipid-lowering treatment on natural history of heterozygous familial hypercholesterolemia in past three decades","volume":"108","author":"Elis","year":"2011","journal-title":"Am. J. Cardiol."},{"issue":"9256","key":"10.1016\/j.atherosclerosis.2016.03.017_bib18","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S0140-6736(00)04053-8","article-title":"Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial","volume":"357","author":"Smilde","year":"2001","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.atherosclerosis.2016.03.017_bib19","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1016\/j.jpeds.2015.02.043","article-title":"Efficacy and safety of ezetimibe monotherapy in children with heterozygous familial or nonfamilial hypercholesterolemia","volume":"166","author":"Kusters","year":"2015","journal-title":"J.\u00a0Pediatr."},{"issue":"9","key":"10.1016\/j.atherosclerosis.2016.03.017_bib20","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1007\/s11886-015-0629-1","article-title":"Optimizing treatment of familial hypercholesterolemia in children and adolescents","volume":"17","author":"Luirink","year":"2015","journal-title":"Curr. Cardiol. Rep."},{"issue":"3","key":"10.1016\/j.atherosclerosis.2016.03.017_bib21","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1161\/CIRCOUTCOMES.111.000014","article-title":"Journey through cholesteryl ester transfer protein inhibition: from bench to bedside","volume":"6","author":"Karalis","year":"2013","journal-title":"Circ. Cardiovasc Qual. Outcomes"},{"issue":"3","key":"10.1016\/j.atherosclerosis.2016.03.017_bib22","first-page":"291","article-title":"Therapeutic implications of cholesteryl ester transfer protein inhibitors in hyperlipidemia and low high-density lipoprotein-cholesterolemia","volume":"4","author":"Inazu","year":"2003","journal-title":"Curr. Opin. Investig. Drugs"},{"issue":"6","key":"10.1016\/j.atherosclerosis.2016.03.017_bib23","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1161\/01.ATV.17.6.1053","article-title":"Genetic cholesteryl ester transfer protein deficiency is extremely frequent in the Omagari area of Japan. Marked hyperalphalipoproteinemia caused by CETP gene mutation is not associated with longevity","volume":"17","author":"Hirano","year":"1997","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"5 Pt 1","key":"10.1016\/j.atherosclerosis.2016.03.017_bib24","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1006\/pmed.1998.0340","article-title":"A\u00a0low prevalence of coronary heart disease among subjects with increased high-density lipoprotein cholesterol levels, including those with plasma cholesteryl ester transfer protein deficiency","volume":"27","author":"Moriyama","year":"1998","journal-title":"Prev. Med."},{"issue":"9","key":"10.1016\/j.atherosclerosis.2016.03.017_bib25","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1016\/j.jacc.2006.06.066","article-title":"Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels on a background of atorvastatin","volume":"48","author":"McKenney","year":"2006","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"issue":"22","key":"10.1016\/j.atherosclerosis.2016.03.017_bib26","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa1206797","article-title":"Effects of dalcetrapib in patients with a recent acute coronary syndrome","volume":"367","author":"Schwartz","year":"2012","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"2","key":"10.1016\/j.atherosclerosis.2016.03.017_bib27","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/MJT.0b013e31828b8463","article-title":"Systematic review of CETP inhibitors for increasing high-density lipoprotein cholesterol: where do these agents stand in the approval process?","volume":"22","author":"Bishop","year":"2015","journal-title":"Am. J. Ther."},{"issue":"6","key":"10.1016\/j.atherosclerosis.2016.03.017_bib28","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/clpt.2008.109","article-title":"Multiple-dose pharmacodynamics and pharmacokinetics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects","volume":"84","author":"Krishna","year":"2008","journal-title":"Clin. Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2016.03.017_bib29","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.atherosclerosis.2013.05.012","article-title":"Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib in Japanese patients with dyslipidemia","volume":"230","author":"Teramoto","year":"2013","journal-title":"Atherosclerosis"},{"issue":"25","key":"10.1016\/j.atherosclerosis.2016.03.017_bib30","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1056\/NEJMoa1009744","article-title":"Safety of anacetrapib in patients with or at high risk for coronary heart disease","volume":"363","author":"Cannon","year":"2010","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"9983","key":"10.1016\/j.atherosclerosis.2016.03.017_bib31","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1016\/S0140-6736(14)62115-2","article-title":"Anacetrapib as lipid-modifying therapy in patients with heterozygous familial hypercholesterolaemia (REALIZE): a randomised, double-blind, placebo-controlled, phase 3 study","volume":"385","author":"Kastelein","year":"2015","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.atherosclerosis.2016.03.017_bib32","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1194\/jlr.M032615","article-title":"Measurement of LDL-C after treatment with the CETP inhibitor anacetrapib","volume":"54","author":"Davidson","year":"2013","journal-title":"J.\u00a0Lipid Res."},{"issue":"Series B","key":"10.1016\/j.atherosclerosis.2016.03.017_bib33","first-page":"134","article-title":"Longitudinal data analysis of continuous and discrete responses for pre-post designs","volume":"62","author":"Liang","year":"2000","journal-title":"Indian J. Stat."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2016.03.017_bib34","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jacl.2014.10.005","article-title":"Effects of anacetrapib on plasma lipids in specific patient subgroups in the DEFINE (Determining the Efficacy and Tolerability of CETP INhibition with AnacEtrapib) trial","volume":"9","author":"Brinton","year":"2015","journal-title":"J.\u00a0Clin. Lipidol."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2016.03.017_bib35","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.amjcard.2013.08.041","article-title":"Evaluation of lipids, drug concentration, and safety parameters following cessation of treatment with the cholesteryl ester transfer protein inhibitor anacetrapib in patients with or at high risk for coronary heart disease","volume":"113","author":"Gotto","year":"2014","journal-title":"Am. J. Cardiol."},{"issue":"9","key":"10.1016\/j.atherosclerosis.2016.03.017_bib36","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1016\/j.jacc.2006.06.067","article-title":"Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels","volume":"48","author":"Davidson","year":"2006","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"issue":"21","key":"10.1016\/j.atherosclerosis.2016.03.017_bib37","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1056\/NEJMoa0706628","article-title":"Effects of torcetrapib in patients at high risk for coronary events","volume":"357","author":"Barter","year":"2007","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"13","key":"10.1016\/j.atherosclerosis.2016.03.017_bib38","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1056\/NEJMoa070635","article-title":"Effect of torcetrapib on the progression of coronary atherosclerosis","volume":"356","author":"Nissen","year":"2007","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"9582","key":"10.1016\/j.atherosclerosis.2016.03.017_bib39","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0140-6736(07)61088-5","article-title":"Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial","volume":"370","author":"Bots","year":"2007","journal-title":"Lancet"}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915016300922?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915016300922?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,14]],"date-time":"2018-09-14T02:56:01Z","timestamp":1536893761000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915016300922"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":39,"alternative-id":["S0021915016300922"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2016.03.017","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2016,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib in Japanese patients with heterozygous familial hypercholesterolemia","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2016.03.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}